Drug Information

Drug (ID: DG00087) and It's Reported Resistant Information

• Name: Progesterone
• Synonyms: Progesterone; 57-83-0; Agolutin; Pregn-4-ene-3,20-dione; Luteohormone; Crinone; 4-Pregnene-3,20-dione; Utrogestan; Syngesterone; Progestin; Luteol; Corpus luteum hormone; Progesterol; Progesteronum; Pregnenedione; Glanducorpin; Prometrium; Corlutin; Cyclogest; Progestron; Gestormone; Progestone; Gestone; Progestasert; Progestronol; Methylpregnone; Hormoflaveine; Syngestrets; Proluton; Progekan; Nalutron; Lutoform; Gynlutin; Gesterol; Fologenon; Corporin; Corlutina; Syntolutan; Prolidon; Membrettes; Lutocyclin; Luteodyn; Lucorteum; Corluvite; LPCN-1107; Progesterone (oral, preterm labor); Progesterone (oral, preterm labor), Lipocine
• Indication:
  In total 2 Indication(s)
  Preterm labour/delivery [ICD-11: JB00]; Approved; [1]
  Contraceptive management [ICD-11: QA21]; Phase 3; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Endometrial cancer [ICD-11: 2C76]; [1]
• Target: Progesterone receptor (PGR); PRGR_HUMAN; [1]
• Formula: C21H30O2
• IsoSMILES: CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
• InChI: 1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1
• InChIKey: RJKFOVLPORLFTN-LEKSSAKUSA-N
• PubChem CID: 5994
• ChEBI ID: CHEBI:17026
• TTD Drug ID: D07BSQ
• VARIDT ID: DR00281
• INTEDE ID: DR1346
• DrugBank ID: DB00396

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Endometrial cancer [ICD-11: 2C76]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Nuclear paraspeckle assembly transcript 1 (NEAT1) [1]

• Molecule Alteration: Expression; Down-regulation
• Resistant Disease: Endometrial cancer [ICD-11: 2C76.1]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Activation; hsa04210
• Cell Pathway Regulation: Cell cycle arrest; Activation; hsa04110
• In Vitro Model: 293T cells; Breast; Homo sapiens (Human); CVCL_0063
• In Vitro Model: Ishikawa cells; Endometrium; Homo sapiens (Human); CVCL_2529
• Experiment for Molecule Alteration: Microarray
• Experiment for Drug Resistance: Flow cytometry assay
• Mechanism Description: Progesterone Repressed LncRNA NEAT1,LEF1, c-myc, and MMP9 in Wnt/beta-catenin Signaling Pathway via Inhibition of NEAT1/miRNA-146b-5p Axis in Endometrial Cancer.

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Lymphoid enhancer-binding factor 1 (LEF1) [1]

• Molecule Alteration: Expression; Down-regulation
• Resistant Disease: Endometrial cancer [ICD-11: 2C76.1]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Inhibition; hsa04210
• Cell Pathway Regulation: Cell colony; Activation; hsa05200
• Cell Pathway Regulation: Cell cycle; Activation; hsa04110
• In Vitro Model: 293T cells; Breast; Homo sapiens (Human); CVCL_0063
• In Vitro Model: Ishikawa cells; Endometrium; Homo sapiens (Human); CVCL_2529
• Experiment for Molecule Alteration: Western blot analysis
• Experiment for Drug Resistance: Flow cytometry assay
• Mechanism Description: Progesterone Repressed LncRNA NEAT1,LEF1, c-myc, and MMP9 in Wnt/beta-catenin Signaling Pathway via Inhibition of NEAT1/miRNA-146b-5p Axis in Endometrial Cancer.

References

• Ref 1: Investigations on the mechanism of progesterone in inhibiting endometrial cancer cell cycle and viability via regulation of long noncoding RNA NEAT1/microRNA-146b-5p mediated Wnt/Beta-catenin signaling. IUBMB Life. 2019 Feb;71(2):223-234. doi: 10.1002/iub.1959. Epub 2018 Nov 19.